L. Goldstick

发表

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Margaret Burnett, Gavin Giovannoni, 2018, The Lancet.

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.

H. Lüders, D. Dinner, R. Lesser, 1988, Neurology.

Ipsilateral forced head and eye turning at the end of the generalized tonic‐clonic phase of versive seizures

H. Lüders, H. Morris, E. Wyllie, 1986, Neurology.

Results from a multicenter, randomized, double‐blind, placebo‐controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids

Jeffrey A. Cohen, Aaron E Miller, Derrick Robertson, 2022, CNS neuroscience & therapeutics.

Spinal cord degeneration in AIDS

T. Mandybur, L. Goldstick, R. Bode, 1985, Neurology.

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

D. Arnold, D. Reich, M. Valis, 2021, The Lancet Neurology.

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Alexander Parajeles Vindas, P. Kowey, D. Arnold, 2016, Neurology. Clinical practice.

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.

M. Freedman, M. Gudesblatt, M. Agius, 2014, Multiple sclerosis and related disorders.